Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma. Nierengarten MB. Cancer 2025;131:e35899.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma. Cancer 2025;131:e35899.
PMID: 40528236